Patients with brain tumors can now have hope thanks to’milestone research’ on a new cancer medication.
According to scientists, a GAME-CHANGING treatment for some of the deadliest brain tumors is ready for human testing.
Vorinostat, a cancer medicine, could be the first effective treatment for meningiomas, which form in the membranes that coat the brain and spinal cord, if it is proven. Vorinostat, which is already used to treat lymphoma in the United States, inhibited the growth of the most aggressive tumors in mice. After splitting tumors into four groups instead of the existing three, experts discovered the potential cure.
According to researchers, this move allows doctors to better forecast how cancer will behave and whether it will return.
The technique could also aid in the discovery of various treatment options based on the disease’s biological causes.
Dr. David Jenkinson of The Brain Tumour Charity, which helped fund the study at Toronto University in Canada, asked for vorinostat to be tested in humans as soon as possible.
“These are incredibly interesting findings,” he added, “and we hope that they will now lead to a paradigm shift in the diagnosis and treatment of meningiomas.”
Dr. Jenkinson believes that the new classification of four molecular groupings will assist doctors identify patients who require more aggressive treatment sooner rather than waiting. “It’s really exciting that an existing lymphoma medicine has been discovered to target the biological drivers of the most aggressive meningiomas – and could represent the first ever therapeutic treatment for the condition,” he added. See the most recent Covid vaccine statistics below, and go to InYourArea for the most recent Covid vaccine news. “For many years, patients have typically had numerous rounds of surgery and radiation, thankfully with very little long-term consequences,” stated study leader Dr Farshad Nassiri.
“However, thanks to a better understanding of the disease’s biology, we’ve discovered the possibility of a medical treatment that could change the landscape for our patients.”
The study, which was published in the journal Nature, looked at the properties of 121 meningiomas, including DNA and proteins. Meningiomas affect more than a fifth of the 12,000 persons in the UK who are diagnosed with a primary brain tumor each year.
More over 80% of grade one [the least aggressive kind]patients live for at least five years after diagnosis, compared to less than 60% of grade three patients.
Vorinostat could be used to treat MG4 tumors, which are the most aggressive and have the lowest survival rates, according to researchers who split the tumors into four new groups, MG1-MG4.
Tammy Andrews, a meningioma patient, called. “Brinkwire News Summary.”